CagriSema: Why Lean Mass May Be the Real Story
The 22.7% weight loss number doesn’t tell the whole story.
CagriSema — Novo Nordisk’s combination of semaglutide plus cagrilintide, an amylin analogue — posted that figure in REDEFINE 1. It’s impressive. It’s also incomplete. Because the more interesting question isn’t just how much weight patients lost. It’s what they lost. And on that front, CagriSema may have an edge over single-pathway GLP-1s that we haven’t fully sorted out yet.
The drug is currently before the FDA. A decision is expected late 2026 or early 2027.
Two Pathways Instead of One
Semaglutide (Wegovy / Ozempic) works on the GLP-1 receptor. Cagrilintide works on the amylin receptor. Different brain regions, different satiety signals, different mechanisms of action. The hunger-suppressing effects appear additive — you’re hitting the appetite control system from two angles instead of one.
The two-pathway design has a theoretical advantage that goes beyond weight loss numbers: lean mass preservation. When you lose weight on a single-pathway GLP-1, a meaningful portion of what you shed is muscle — somewhere in the range of 25–40% of total weight lost, based on what we’ve seen with semaglutide and tirzepatide. Nobody talks about this enough. Losing weight is easy. Losing fat while holding onto muscle is the hard part.
The amylin pathway may help here. Cagrilintide monotherapy trials suggested better lean mass preservation compared to what we’d expect from caloric restriction alone.
There’s also a sex-based angle worth noting. Amylin-based therapies have shown somewhat greater weight loss effects in women in earlier trials. Whether that carries through to the CagriSema combination remains to be confirmed in the stratified analyses — but it’s a reasonable expectation given the pharmacology, and something I’ll be watching in the subgroup data.
The Numbers — Simplified
REDEFINE 1 (patients with obesity, no diabetes): 22.7% mean weight loss at 68 weeks. Forty percent of patients lost 25% or more of their body weight. That’s bariatric surgery territory for a lot of people.
REDEFINE 2 (patients with obesity and type 2 diabetes): 15.7% weight loss plus a 1.91% reduction in A1C. Seventy-four percent got their A1C below 6.5%. Both endpoints superior to semaglutide alone.
REDEFINE 4 (head-to-head against tirzepatide at 84 weeks): CagriSema came in at 23%. Tirzepatide came in at 25.5%. CagriSema missed non-inferiority — it didn’t quite keep up. Zepbound wins on raw efficacy.
The Side Effects Deserve a Real Conversation
The GI side effect profile is the thing I spend the most time explaining to patients before they start any GLP-1. With CagriSema, that conversation is even more important.
Nausea hit roughly 55% of patients in the Phase 3 trials. Vomiting was around 25%. Diarrhea about 32%. These are higher than semaglutide alone. Most events were mild to moderate and clustered during dose escalation in the first few weeks — but “most” doesn’t mean “all.” Some patients had a rough time.
The trial investigators managed this carefully: slow titration, proactive anti-emetic use, dose holds when needed. Discontinuation rates stayed in the low single digits. In the real world — without that level of hand-holding — the side effect burden will be higher. Some patients won’t make it to the target dose. Some won’t stay on the drug long enough to see results.
The Competition
CagriSema isn’t entering an empty field. Survodutide (Boehringer Ingelheim) posted 16.6% weight loss in Phase 3 — not as high as CagriSema, but it adds GLP-1 dual receptor agonism. Different mechanism, still competitive. And Retatrutide (Eli Lilly) cleared 30% weight loss in Phase 2 — a triple hormone receptor agonist (GLP-1, GIP, and glucagon) that is now in Phase 3. If those results hold, it outperforms CagriSema on raw efficacy.
The obesity drug pipeline is moving fast. By the time CagriSema launches, the competitive landscape will be different than it is today. That’s worth knowing — because the right drug for you may not be the one that’s approved first.
Is CagriSema Right for You?
Currently, CagriSema is the best next-step option I’m aware of for patients who’ve plateaued on Wegovy — particularly those who lost a meaningful amount of weight (15%+), have hit a stall, and want to push further without switching drug classes. The combination approach is also worth considering for patients who’ve struggled with muscle preservation during weight loss, though I’ll be reviewing the final lean mass data before making strong recommendations.
If you’re currently on a single-pathway GLP-1 and it’s working — you’re losing weight, you’re tolerating it, your labs are improving — there’s no reason to switch. The best drug is the one you’re actually on.
FDA decision expected late 2026 or early 2027. It’s worth having the conversation now so you’re not caught off guard when it arrives.
Research Brief | Dr. Ethan Lazarus, MD, MFOMA | Clinical Nutrition Center | August 6, 2026